Table 1.
Data from clinical trials of anti-angiogenic drugs combined with immunotherapy for the treatment of NSCLC
| NCT ID | Relevant Compound(s) | Phase | Outcome Measures | Status | Study Title |
|---|---|---|---|---|---|
| NCT02366143 | Atezolizumab + Bevacizumab + Paclitaxel + Carboplatin | Ⅲ | PFS, 8.3 (95% CI, 7.7-9.8) OS, 19.2 (95% CI, 17.0-23.8) |
Completed | A Study of Atezolizumab in Combination with Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab in Participants with Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) |
| NCT02039674 | Pembrolizumab + Paclitaxel + Carboplatin + Bevacizumab | I/II | Objective Response Rate, DLT |
Completed | A Study of Pembrolizumab (MK-3475) in Combination with Chemotherapy or Immunotherapy in Participants with Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021) |
| NCT01454102 | Bevacizumab + Nivolumab | I | ORR, 16.7% (95% CI, 2.1-48.4%) PFSR, 58.3% (95% CI, 27.0-80.1%) |
Completed | Study of Nivolumab (BMS-936558) in Combination with Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects with Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) |
| NCT01633970 | Atezolizmab + Bevacizumab | I | DLT | Completed | A Study of Atezolizumab Administered in Combination with Bevacizumab and/or with Chemotherapy in Participants with Locally Advanced or Metastatic Solid Tumors |
| NCT02443324 | Ramucirumab + Pembrolizumab | I | DLT, DCR, Objective Response Rate |
Active, not recruiting | A Study of Ramucirumab Plus Pembrolizumab in Participants with Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer |
| NCT02856425 | Pembrolizumab + Nintedanib | I | MTD | Recruiting | Trial of Pembrolizumab and Nintedanib |
| NCT04046614 | Nintedanib + Nivolumab | I/II | PFS, ORR | Recruiting | Feasibility and Safety of Nintedanib in Combination with Nivolumab in Pretreated Patients with Advanced or Metastatic NSCLC of Adenocarcinoma Histology |
| NCT03377023 | Nivolumab + Ipilimumab + Nintedanib | I/II | MTD, DCR, Objective Response Rate |
Active, not recruiting | Phase I/II Study of Nivolumab and Ipilimumab Combined with Nintedanib in Non-Small Cell Lung Cancer |
| NCT03689855 | Ramucirumab + Atezolizumab | II | ORR OS PFS |
Active, not recruiting | Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC |
| NCT00828009 | Bevacizumab + Tecemotide | II | PFS, 14.9 (95% CI, 11.0-20.9) OS, 42.7 (95% CI, 21.7-63.3) |
Completed; results published |
BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients with Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery |
| NCT02574078 | Bevacizumab + Nivolumab | I/II | PFS, 6.7 (4.1-NA) OS, 30.8 (8.8-NA) |
Completed; results published |
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) |
| NCT02681549 | Pembrolizumab + Bevacizumab | II | BMRR, ORR | Recruiting | Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer |
| NCT03527108 | Nivolumab + Ramucirumab | II | DCR, ORR, PFS | Recruiting | Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC |
| NCT02572687 | Ramucirumab + MEDI4736 | I | DLT, ORR, DCR | Completed | A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies |
| NCT03786692 | Carboplatin + Pemetrexed + Bevacizumab + Atezolizumab | II | PFS, ORR | Recruiting | Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC |
| NCT02174172 | Atezolizumab + PEG-interferon alfa-2a + Bevacizumab | I | RP2D, RECIST | Completed | A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other immune-modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors |
| NCT03616691 | Atezolizumab+ Bevacizumab | II | ORR, PFS | Unknown | Atezolizumab Monotherapy and Consequent Therapy With Atezolizumab Plus Bevacizumab for NSCLC |
| NCT03647956 | Atezolizumab + Bevacizumab | II | Objective response rate, PFS, TTP, DoR |
Unknown | Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors |
| NCT03713944 | Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab | II | PFS, ORR, DCR | Active, not recruiting | Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer |
| NCT03836066 | Atezolizumab + Bevacizumab | II | Efficacy of atezolizumab in combination with bevacizumab | Active, not recruiting | Atezolizumab Plus Bevacizumab in First-Line NSCLC Patients |
PFS: progression-free survival; OS: overall survival; CI: confidence interval; ORR: overall response rate; PFSR: progression-free survival rate; DLT: Dose-limiting toxicity; DCR: disease control rate; MTD: maximum tolerated dose; BMRR: brain metastasis response rate; RP2D: recommended phase II dose; RECIST: response evaluation criteria in solid Tumors; TTP: time to progression; DoR: duration of response.